Eli Lilly will be presenting data from studies on multiple GLP-1 drugs later this month. Encouraging data on GLP-1 treatments in its pipeline could help give the stock a big boost. Concerns about ...

Eli Lilly is no longer just a pharmaceutical giant—it’s becoming a platform company that’s reshaping the very structure of global healthcare.

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an overreaction to GLP-1 news.

Eli Lilly (LLY) reported first quarter earnings on Thursday, beating Wall Street's expectations on the top and bottom lines, but its stock sank more than 11% in trading despite the win. The ...

Given this positive news and the subsequent stock rise, the question is whether Eli Lilly is a buy at around $820. Our analysis suggests it is. We have reached this conclusion by comparing Eli ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership. Read more about LLY stock here.

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial results.

Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth initiatives. Click for my LLY update.

Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.